Sugi Predict

Sugi Predict / Compounds / SCHEMBL157000

SCHEMBL157000

SCHEMBL157000

CCc1ccc(C(O)c2c[nH]c3ccccc23)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR84 Q9NQS5 3/20 0.54
▸ FFAR1 O14842 2/20 0.51
▸ MAPT P10636 3/20 0.50
▸ HTR2A P28223 1/20 0.48
▸ HTR2C P28335 1/20 0.48
▸ HTR2B P41595 1/20 0.48
▸ STING1 Q86WV6 1/20 0.47
▸ AHR P35869 1/20 0.46
▸ MGAM O43451 4/20 0.45
▸ GAA P10253 4/20 0.45
▸ SI P14410 4/20 0.45
▸ MGAM2 Q2M2H8 4/20 0.45
▸ CFTR P13569 1/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ USP2 O75604 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21399874 0.85 NR3C1 (0.57) GPR84FFAR1MAPTHTR2AHTR2C
SCHEMBL13763231 0.82 MAPT (0.59) GPR84FFAR1MAPTHTR2AHTR2C
SCHEMBL27714156 0.80 MAPT (0.54) GPR84FFAR1MAPTHTR2AHTR2C
SCHEMBL18364667 0.80 MAPT (0.54) GPR84FFAR1MAPTHTR2AHTR2C
SCHEMBL28767073 0.80 MAPT (0.54) GPR84FFAR1MAPTHTR2AHTR2C
SCHEMBL13763230 0.80 MGAM (0.58) GPR84FFAR1MAPTHTR2AHTR2C
SCHEMBL27714368 0.80 MEN1 (0.56) GPR84FFAR1MAPTHTR2AHTR2C
SCHEMBL8213938 0.79 MAPT (0.67) GPR84FFAR1MAPTHTR2AHTR2C
SCHEMBL1992184 0.77 MAPT (0.61) GPR84FFAR1MAPTHTR2AHTR2C
SCHEMBL13763220 0.77 GUSB (0.51) GPR84FFAR1MAPTSTING1AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3251679-B1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER MITSUBISHI TANABE PHARMA CORP (JP) 2020-12-16 — — EP disclosed
EP-2896397-B2 Novel compounds having inhibitory activity against sodium-dependant glucose transporter MITSUBISHI TANABE PHARMA CORP (JP) 2020-10-07 — — EP disclosed
EP-1651658-B2 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER MITSUBISHI TANABE PHARMA CORP (JP) 2020-08-12 — — EP disclosed
US-20180282363-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2018-10-04 — — US disclosed
EP-3251679-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER Mitsubishi Tanabe Pharma Corporation (JP) 2017-12-06 — — EP disclosed
EP-2896397-B1 Novel compounds having inhibitory activity against sodium-dependant glucose transporter MITSUBISHI TANABE PHARMA CORP (JP) 2017-09-06 — — EP disclosed
US-20160108078-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2016-04-21 — — US disclosed
EP-2896397-A1 Novel compounds having inhibitory activity against sodium-dependant glucose transporter Mitsubishi Tanabe Pharma Corporation (JP) 2015-07-22 — — EP disclosed
EP-2514756-B1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT GLUCOSE TRANSPORTER MITSUBISHI TANABE PHARMA CORP (JP) 2014-12-17 — — EP disclosed
CN-104109155-A Novel compounds TANABE SEIYAKU CO 2014-10-22 — — CN disclosed
US-8202984-B2 Glucopyranoside compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-19 — — US disclosed
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-08 — — US disclosed
US-7943788-B2 Including the antidiabetic, antiobesity sodium glucose transport inhibitor Canagliflozin (1-( beta -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-17 — — US disclosed
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-05-05 — — US disclosed
CN-101111492-B Indole derivatives TANABE SEIYAKU CO 2010-09-22 — — CN disclosed
CN-101111492-A Indole derivatives TANABE SEIYAKU CO (JP) 2008-01-23 — — CN disclosed
CN-1829729-A Novel compounds TANABE SEIYAKU CO (JP) 2006-09-06 — — CN disclosed
EP-1651658-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2006-05-03 — — EP disclosed
US-20050233988-A1 Novel compounds TANABE SEIYAKU CO., LTD. (JP) 2005-10-20 — — US disclosed
WO-2005012326-A1 NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDANT TRANSPORTER TANABE SEIYAKU CO., LTD. (JP) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058941-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 GPR84 3360/4885FFAR1 2022/4885MAPT 3581/4885
US-20050233988-A1 Novel compounds CYP1B1, CYP4B1, CYP2B6 GPR84 2892/4885FFAR1 1301/4885MAPT 3756/4885
US-20110105424-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 GPR84 3360/4885FFAR1 2022/4885MAPT 3581/4885
US-20180282363-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 GPR84 3360/4885FFAR1 2022/4885MAPT 3581/4885
US-20160108078-A1 GLUCOPYRANOSIDE COMPOUND UGGT1, B3GAT3, FUT6 GPR84 3360/4885FFAR1 2022/4885MAPT 3581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.